Skip to main content

Market Overview

Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead Candidate

  • Cassava Sciences Inc (NASDAQ: SAVA) has entered into a definitive agreement with several institutional investors for the purchase of 4.1 million common shares at $49 per share, for gross proceeds of approximately $200 million, in a registered direct offering. The offer price is at a 15% discount from the last close price of $57.56 on Tuesday.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering and is expected to close by February 12.
  • Cassava Sciences intends to use the net proceeds to develop simufilam, its lead drug candidate for Alzheimer's disease.
  • Earlier this week, shares rallied after the company announced expanding the size of the ongoing simufilam open-label study and its plans to initiate a six-month study in patients who complete at least one year of open-label treatment with simufilam.
  • Price Action: SAVA dropped 12.7% at $50.27 during premarket trading hours on the last check Wednesday.

Related Articles (SAVA)

View Comments and Join the Discussion!

Posted-In: Alzheimer’sBiotech News Offerings FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at